Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Proliferation Of Fake COVID-19 Vaccines Driven By Unequal Access

Several Cases Have Been Detected In Mexico

Executive Summary

The lack of availability of coronavirus vaccines in many less well off parts of the world is an open invitation to criminals seeking to sell falsified or substandard versions. Many instances of vaccine theft and diversion have also been found.

You may also be interested in...



COVID-19 Products Still Vulnerable To Falsification & Diversion

High demand for genuine COVID-19 products, together with related product shortages, has fueled the proliferation of falsified, substandard and counterfeit vaccines, medicines and diagnostic tests.

Speed Bumps Ahead For IP Waiver But Will It Nudge Voluntary Licensing?

IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.

Speed Bumps Ahead For IP Waiver But Will It Nudge Voluntary Licensing?

IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144198

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel